What is Sera Prognostics?
Sera Prognostics operates at the intersection of biotechnology and maternal healthcare, specializing in the development of advanced diagnostic tests. The company's core mission is to provide clinicians and expectant mothers with actionable insights regarding the individualized risk of premature birth, preeclampsia, and other critical pregnancy complications. By leveraging proprietary biological markers, Sera Prognostics empowers healthcare providers to implement personalized care plans, effectively shifting the paradigm from reactive treatment to proactive, data-driven intervention in high-risk pregnancies.
How much funding has Sera Prognostics raised?
Sera Prognostics has raised a total of $325M across 11 funding rounds:
Debt
$4.5M
Private Equity
$9.2M
Private Equity
$5M
Series B
$25M
Debt
$10M
Series C
$40M
Series D
$36M
Debt
$1M
Series E
$100M
Share Placement
$75M
Debt (2013): $4.5M led by Catalyst Health Ventures, InterWest Partners, Linden, and UpStart Ventures
Private Equity (2014): $9.2M, investors not publicly disclosed
Private Equity (2014): $5M, investors not publicly disclosed
Series B (2015): $25M backed by Domain Associates, Catalyst Health Ventures, Bill & Melinda Gates Foundation, and InterWest Partners
Debt (2015): $10M with participation from Square 1 Bank
Series C (2017): $40M led by Catalyst Health Ventures, Laboratory Corporation of America, Bill & Melinda Gates Foundation, InterWest Partners, and Domain Associates
Series D (2019): $36M supported by Labcorp, Domain Associates, Chione , Ltd, Blue Ox Healthcare Partners, InterWest Partners, and Catalyst Health Ventures
Debt (2020): $1M featuring PPP
Series E (2021): $100M backed by Parian Global, aMoon, Anthem, Blue Ox Healthcare Partners, and Vivo Capital
Share Placement (2021): $75M, investors not publicly disclosed
Key Investors in Sera Prognostics
aMoon
aMoon is a healthcare investment firm that partners with exceptional scientists and entrepreneurs to build companies focused on transforming healthcare through technology and biology.
Blue Ox Healthcare Partners
Blue Ox Healthcare Partners is a commercial-stage growth investor focused on precision health and individualized medicine, guiding companies through the commercialization process.
Labcorp
Labcorp Holdings Inc. is a global laboratory services company that provides vital diagnostic information to help doctors, hospitals, and patients make clear and confident health decisions.
What's next for Sera Prognostics?
With the recent influx of capital, Sera Prognostics is well-positioned to accelerate the commercialization of its diagnostic suite and expand its footprint within the global healthcare ecosystem. The company's strategic roadmap likely involves deepening its clinical validation studies and enhancing its digital health infrastructure to ensure broader accessibility. As the firm transitions into its next phase of growth, the focus will remain on scaling operations to meet the rising demand for precision diagnostics, ultimately aiming to reduce the incidence of adverse birth outcomes and improve long-term health metrics for both mothers and infants.
See full Sera Prognostics company page
